Three focus areas to accelerate breakthrough drugs to market

09:00 EDT 11 Oct 2019 | Pharmafile
The pace of R&D innovation is getting treatments to patients faster, but it is also putting pressure on clinical operations teams. There are now more complexities in running trials and organizations have a greater need for improved trial efficiency.

The number of clinical trials taking place each year continues to rise. In fact, in 2018, the FDA approved a record-breaking 59 drugs[i]. Volumes are increasing, in part, due to the shift towards precision medicine. And the impact these drugs are having on patient lives is significant. For example, it was recently announced that NHS patients with lymphoma are being given a pioneering treatment that genetically reprograms their immune system to fight cancer.[ii]

read more

Original Article: Three focus areas to accelerate breakthrough drugs to market


More From BioPortfolio on "Three focus areas to accelerate breakthrough drugs to market"

Quick Search

Relevant Topics

Clinical Approvals
Clinical trials are a set of procedures in medical research conducted to allow safety (or more specifically, information about adverse drug reactions and adverse effects of other treatments) and efficacy data to be collected for health interventions (e.g...

Drug Approvals
In order to become availible to pateints, drugs need to undergo a number of phases of clinical trials to test their efficacy and safty and to then be authorised by the drug approval organistion in each respective country. This is the FDA in the USA and N...